Ono files for approval of intravenous Emend in Japan
This article was originally published in Scrip
Merck & Co's licensee, Ono Pharmaceutical, has filed an approval application in Japan for the intravenous form of Emend (aprepitant) for the prevention of chemotherapy-induced nausea and vomiting.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.